Clinical Trials Browser

CD19-positive Relapsed or Refractory B-cell Malignancies × fludarabine × 1 year × Clear all

NCT06092047 2025-05-16

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Phase EARLY_PHASE1 Recruiting

CD19-positive Relapsed or Refractory B-cell Malignancies